ARMP 10-Q: SEC filing

Armata Pharmaceuticals

Filed with the SEC on · accession 0001104659-26-126277

ARMP filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -4.4% by the first close after the filing.

Summary of the filing

Armata Pharmaceuticals filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing routine financial results and ongoing financing arrangements with Innoviva Strategic Opportunities LLC.

Key details

Lender and warrant holderInnoviva Strategic Opportunities LLC

How ARMP stock reacted

Close before

$3.89

Nov 11, 2026

First close after

-4.37%

$3.72

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ARMP, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ARMP?

Click here

Frequently asked questions

What did ARMP file with the SEC on Nov 12, 2026?

ARMP filed a 10-Q (SEC filing). Armata Pharmaceuticals filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing routine financial results and ongoing financing arrangements with Innoviva Strategic Opportunities LLC.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did ARMP stock react to this filing?

ARMP closed at $3.89 before the filing and $3.72 on Nov 12, 2026 (-4.37%).

Other ARMP SEC filings

Get alerts when ARMP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days